Regen BioPharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Regen BioPharma has a total shareholder equity of $-5.2M and total debt of $794.7K, which brings its debt-to-equity ratio to -15.3%. Its total assets and total liabilities are $177.6K and $5.4M respectively.

Belangrijke informatie

-15.3%

Verhouding schuld/eigen vermogen

US$794.70k

Schuld

Rente dekkingsratio	n/a
Contant	US$716.00
Aandelen	-US$5.19m
Totaal verplichtingen	US$5.37m
Totaal activa	US$177.61k

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: RGBP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Langlopende schulden: RGBP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: RGBP has negative shareholder equity, which is a more serious situation than a high debt level.

Schuld verminderen: RGBP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Insufficient data to determine if RGBP has enough cash runway based on its current free cash flow.

Voorspelling contante baan: Insufficient data to determine if RGBP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Regen BioPharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells

Regen BioPharma, Inc. Outlines Future Steps in CAR T Program

Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program

Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly

Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies

Regen BioPharma, Inc. Announces Board Appointments

Regen BioPharma, Inc. Develops a Non-Exhaustible CAR-T Cell Therapeutic

Regen BioPharma, Inc. Files Provisional Patent on Car-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy

Regen Biopharma Develops Novel Means of Using Car-T Cell Immunotherapy to Attack Solid Tumors

Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors

Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine

Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology

Regen Biopharma, Inc. Enters into Settlement Negotiations with the Plaintiff in Order to Resolve This Dispute in Mutually Acceptable Manner

Regen Biopharma, Inc. Executes Consulting Agreement with Biotech Research Group Corporation

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven